Peptides Similar to Larazotide

Compounds Related to Larazotide#

Larazotide occupies a unique niche as a tight junction regulator. There are no directly comparable peptide therapeutics approved or in advanced development. The most relevant comparisons are with other investigational celiac disease therapies and with peptides that affect gastrointestinal function.

Celiac Disease Pipeline Comparisons#

While not peptides, several other therapeutic approaches for celiac disease are in development:

• Gluten-degrading enzymes (e.g., latiglutenase): Enzymatic degradation of gluten peptides in the stomach before they reach the small intestine
• Immune tolerance approaches (e.g., Nexvax2, discontinued): Peptide-based desensitization to gluten epitopes
• Transglutaminase inhibitors: Block tissue transglutaminase from deamidating gluten peptides

Larazotide's approach of blocking intestinal permeability is mechanistically distinct from all of these, as it targets the physical barrier rather than the gluten itself or the immune response.

BPC-157#

BPC-157 is a pentadecapeptide (15 amino acids) with broad cytoprotective and healing properties in the gastrointestinal tract. While both BPC-157 and larazotide have GI-relevant mechanisms, they operate through fundamentally different pathways:

Tight Junction Biology Context#

Larazotide is the only peptide specifically designed to modulate tight junctions through zonulin receptor antagonism. The zonulin pathway has been implicated in multiple conditions beyond celiac disease, including type 1 diabetes, inflammatory bowel disease, and autoimmune conditions, suggesting potential broader applications if the mechanism can be validated in these populations.

Comparison Context#

Larazotide belongs to the Immune category of research peptides. Comparing Larazotide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.

Detailed Comparisons#

The following peptides and compounds are most closely related to Larazotide in mechanism, indication, or therapeutic category:

Larazotide vs BPC-157#

Similarity: Low to moderate - Both are peptides with gastrointestinal protective properties, but through entirely different mechanisms

Key Differences: BPC-157 is a pentadecapeptide with broad tissue-healing properties including GI mucosal protection. Larazotide is an octapeptide that specifically targets zonulin-mediated tight junction opening.

Advantages of BPC-157: Highly specific mechanism targeting a defined pathway, extensive clinical trial data in celiac disease, favorable safety profile

Disadvantages of BPC-157: Phase 3 failure, limited to zonulin pathway dysfunction, investigational status with uncertain development future

Researchers choosing between Larazotide and BPC-157 should consider the development stage, available evidence, and specific research objectives when making their selection.

Related Reading#

• Larazotide overview and research guide
• Larazotide research evidence
• Larazotide dosing protocols